Silva, Cristine G.
HRN: 00-73-06 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/25/2022
CEFOTAXIME 500MG (VIAL)
05/25/2022
05/31/2022
ORAL
500mg
BID
WBC 22
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Non-compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes